A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants

Autor: Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle, Ariel S. Wirchnianski, Robert H. Bortz, Ethan Laudermilch, J. Maximilian Fels, Amanda Mengotto, Ryan J. Malonis, George I. Georgiev, Jose A. Quiroz, Daniel Wrapp, Nianshuang Wang, Kathryn E. Dye, Jason Barnhill, John M. Dye, Jason S. McLellan, Johanna P. Daily, Jonathan R. Lai, Andrew S. Herbert, Laura M. Walker, Kartik Chandran, Rohit K. Jangra
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: mBio, Vol 12, Iss 5 (2021)
Druh dokumentu: article
ISSN: 2150-7511
DOI: 10.1128/mBio.02473-21
Popis: The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.
Databáze: Directory of Open Access Journals